Overview on the effects of progestins on bone

Maturitas

Volumn 46, Issue SUPPL. 1, 2003, Pages 77-87

  Thijssen, Jos H H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bone; Fracture; Gonadotropin; Oestrogens; Progestins

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CORTICOSTEROID; DESOGESTREL PLUS ETHINYLESTRADIOL; DIANE; DIENOGEST; DYDROGESTERONE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE; GESTAGEN; GESTRINONE; GONADORELIN AGONIST; LEVONORGESTREL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NANDROLONE; NOMEGESTROL; NORETHISTERONE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PREDNISONE; PREGNANE DERIVATIVE; PROGESTERONE; PROGESTERONE RECEPTOR; PROMEGESTONE; UNINDEXED DRUG; VITAMIN D;

AGING; BODY MASS; BONE; BONE DEMINERALIZATION; BONE DENSITY; BONE DISEASE; BONE MINERAL; BONE REMODELING; CELL LINE; CLINICAL OBSERVATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTRACEPTION; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG ACTIVITY; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; ENDOCRINE DISEASE; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FALLING; FRACTURE; FRAGILITY FRACTURE; HABIT; HEREDITY; HIP FRACTURE; HORMONAL THERAPY; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; IMMOBILIZATION; IN VITRO STUDY; LIFESTYLE; NONHUMAN; NUTRITION; OSTEOLYSIS; OVARIECTOMY; POSTMENOPAUSE; REVIEW; RISK FACTOR; SECONDARY OSTEOPOROSIS; TREATMENT OUTCOME; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 0344253723     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2003.09.022     Document Type: Article

References (134)

1. Pols H.A.P., Wittenberg J. CBO-Richtlijn 'osteoporosis'. Ned. Tijdschr. Geneeskd. 146:2002;1359-1363.
2. Fox C.M., Cummings S.R., Williams E., Stone K. Femoral neck and intertrochanter fractures have different risk factors: a prospective study. Osteoporos Int. 11:2000;1018-1023.
3. Tosteson A.N., Gabriel S.E., Grove M.R.et al. Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int. 12:2001;1042-1049.
4. NIH Consensus Development Panel on osteoporosis prevention, diagnosis and therapy. Osteoporosis diagnosis, prevention and therapy. JAMA 2001;285:785-95.
5. Grisso J.A., Kelsey J.L., Strom B.L.et al. Risk factors for falls as a cause of hip fractures in women. N. Engl. J. Med. 324:1991;1326-1331.
6. Lauritzen J.B., Petersen K.K., Lund B. Effect of external hip protectors on hip fractures. Lancet. 341:1993;11-13.
7. Ekman A., Mallmin H., Michanelsson K.et al. External hip protectors to prevent osteoporotic fractures. Lancet. 350:1997;563-564.
8. Stalenhoef P.A., Crebolder H.F.J.M., Knottnerus J.A., van der F.G.E.M. Incidence, risk factors and consequences of falls among elderly subjects living in the community: a criteria-based analysis. Eur. J. Publ. Health. 7:1997;328-334.
9. Kaufman J.M., Johnell O., Abadie E.et al. Background for studies on the treatment of male osteoporosis: state of the art. Ann. Rheum. Dis. 59:2000;765-772.
10. Ralston S.H. Genetics of osteoporosis. Bone. 25:1999;85-86.
11. Nguyen T.V., Eisman J.A. Genetics of fracture: challenges and opportunities. J. Bone Miner. Res. 15:2000;1253-1256.
12. Felson D.T., Zhang Y., Hannan M.T.et al. Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J. Bone Miner. Res. 20:1993;141-149.
13. Glynn N.W., Zmuda J.M., Cauley J.A. Weight change and bone mineral density in older men: a longitudinal study. J. Bone Miner. Res. 11:1996;S155.
14. Nordin B.E.C., Morris H.A. The calcium deficiency model of osteoporosis. Nutr. Rev. 47:1989;65-72.
15. Rosen C.J. Pathogenesis of osteoporosis. Ballière's Clin. Endocrin. Metab. 14:2000;181-193.
16. Albright F., Smith P.H., Richardson A.M. Postmenopausal osteoporosis - its clinical features. JAMA. 116:1941;2465-2473.
17. Cauley J.A., Sceley D.G., Ensrud K. Estrogen replacement therapy and fractures in older women. Ann. Intern. Med. 122:1995;9-16.
18. Lindsay R. The burden of osteoporosis: costs. Am. J. Med. 98(Suppl. 2A):1995;9S-11S.
19. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.
20. Greendale G.A., Espeland M., Slone S.et al. Bone mass response to discontimuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Intervention (PEPI) safety follow-up study. Arch. Intern. Med. 162:2002;665-672.
21. Eriksen E.F., Colvard D.S., Berg N.J.et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science. 241:1988;84-86.
22. Wei LL, Leach MW, Miner, et al. Evidence for progesterone receptors in human osteoblast-like cells. Biochem Biophys Res Commun 1993;195:525-32.
23. Graham J.D., Clarke C.L. Physiological action of progesterone in target tissues. Endocr. Rev. 18:1997;502-519.
24. Shibata H., Spencer T.E., Onate S.A.et al. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Rec. Prog. Horm. Res. 52:1997;141-165.
25. Darney P.D. The androgenicity of progestins. Am. J. Med. 98(Suppl. 1A):1995;104S-110S.
26. Ishida Y., Ishida Y., Heersche J.N. Pharmacological doses of medroxyprogesterone may cause bone loss through glucocorticoid activity: an hypothesis. Osteoporos Int. 13:2002;601-605.
27. Trémollieres F.A., Strong D.D., Baylink D.J.et al. Progesterone and promegestone stimulate bone cell proliferation and insulin-like growth factor-2 production. Acta Endocrinol. 126:1992;329-337.
28. Ishida Y., Heersche J.N. Progesterone stimulates proliferation and differentiation of osteoprogenitor cells in bone cell populations derived from adult female but not from adult male rats. Bone. 20:1997;17-25.
29. Verhaar H.J., Damen C.A., Duursma S.A.et al. A comparison of the action of progestins and estrogen on the growth and differentiation of normal adult human osteoblast-like cells in vitro. Bone. 15:1994;307-311.
30. Verhaar H.J., Damen C.A., Duursma S.A.et al. Comparison of the action of 17β-estradiol and progestins with insuline-like growth factors-I/-II and TGF-β-1 on the growth of normal adult human bone forming cells. Maturitas. 21:1995;237-243.
31. Lau K.H., Wang S.P., Linkhart T.A.et al. Picomolar norethindrone in vitro stimulates the cell proliferation and activity of a human osteosarcoma cell line and increases bone collagen synthesis without an effect on bone resorption. J. Bone Miner. Res. 9:1994;695-704.
32. Chen L., Scholler J., Foged N.T. Effects of progesterone on proliferation and differentiation of fetal rat calvarial osteoblasts in vitro. Chung Hua Fu Chan Ko Tsa Chih. 32:1997;538-540.
33. Trémolierres F.A., Capilla F., Cigagna F.et al. Augmentation de la prolifération cellulaire par l'acétate de nomégestrol dans des cultures d'ostéoblastes humains. Reprod. Hum. Horm. X:1997;8-24.
34. Prior J.C. Progesterone as a bone-trophic hormone. Endocr. Rev. 11:1990;386-398.
35. DeCherney A. Bone-sparing properties of oral contraceptives. Am. J. Obstet. Gynecol. 174:1996;15-20.
36. Volpe A., Amram A., Cagnacci A.et al. Biochemical aspects of hormonal contraception: effects on bone metabolism. Eur. J. Contracept. Reprod. Health Care. 2:1997;123-126.
37. Castelo-Branco C., Martinez-de-Osaba M.J., Pons F.et al. Effects on bone mass of two oral contraceptives containing ethinylestradiol and cyproterone acetate or desogestrel: results of a 2-year follow-up. Eur. J. Contracept. Reprod. Health Care. 3:1998;79-84.
38. Speroff L., Rowan J., Symons J.et al. The comparative effect on bone density, endometrium and lipids of continuous hormones as replacement therapy. JAMA. 276:1996;1397-2007.
39. Taneepanichskul S., Intaraprasert S., Theppisai U.et al. Bone mineral density during long-term treatment with Norplant implants and depot medroxyprogesterone acetate. A cross-sectional study of Thai women. Contraception. 56:1997;153-155.
40. Taneepanichskul S., Intaraprasert S., Theppisai U.et al. Bone mineral density in long-term depot medroxyprogesterone acetate acceptors. Contraception. 56:1997;1-3.
41. Gbolade B., Ellis S., Murby B.et al. Bone density in long term users of depot medroxyprogesterone acetate. Br. J. Obstet. Gynaecol. 105:1998;790-794.
42. Tharnprisarn W., Taneepanichskul S. Bone mineral density in adolescent and young Thai girls receiving oral contraceptives compared with depot medoxyprogesterone acetate: a cross-sectional study in young Thai women. Contraception. 66:2002;101-103.
43. Cundy T., Ames R., Horne A.et al. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medoxyprogesterone acetate. J. Clin. Endocr. Metab. 88:2003;78-81.
44. Berenson A.B., Radecki C.M., Grady J.J.et al. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet. Gynecol. 98:2001;576-582.
45. Scholes D., LaCroix A.Z., Ichikawa L.E.et al. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology. 13:2002;581-587.
46. Wanichsetakul P., Kamudhamwas A., Watanaruangkovit P.et al. Bone mineral density at various anatomic sites in women receiving combined oral contraceptives and depot medroxyprogesterone acetate for contraception. Contraception. 65:2002;407-410.
47. Cundy T., Cornish J., Roberts H.et al. Menopausal bone loss in long-term users of depot medoxyprogesterone acetate contraception. Am. J. Obstet. Gynecol. 185:2002;978-983.
48. Hussain S.Y., Massil J.H., Matta W.H.et al. Buserelin in premenstrual syndrome. Gynecol. Endocr. 6:1992;57-64.
49. Dawood M.Y., Lewis V., Ramos J. Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotrophin-releasing hormone agonist and danazol. Fertil. Steril. 52:1989;21-26.
50. Studd J., Leather A.T. The need for add-back with gonadotrophin- releasing hormone agonist therapy. Br. J. Obstet. Gynaecol. 103(Suppl. 14):1996;1-4.
51. Pierce S.J., Gazvani M.R., Farquharson R.G. Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up. Fertil. Steril. 74:2000;964-968.
52. Freundl G., Godtke K., Gnoth C.et al. Steroidal add-back therapy in patients treated with GnRH-agonists. Gynecol. Obstet. Invest. 45(Suppl. 1):1998;22-30.
53. Castelo-Branco C., Martinez-de-Osaba M.J., Pons F.et al. Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: effects on hair, bone, and hormone profile after 1-year use. Metabolism. 46:1997;437-440.
54. Surrey E.S. Add-back therapy: extending safety and efficacy of GnRH analogues in the gynecologic patient. Gynecol. Obstet. Invest. 45(Suppl. 1):1998;31-35.
55. Hornstein M.D., Surrey E.S., Weisberg G.W.et al. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet. Gynecol. 91:1998;16-24.
56. Franke H.R., van de Weijer P.H., Pennings T.M.et al. Gonadotropin- releasing hormone agonist plus "add-back" hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertil. Steril. 74:2000;534-539.
57. Kiesel L., W K., Sillem M.et al. Should add-back therapy for endometriosis be deferred for optimal results? Br. J. Obstet. Gynaecol. 103(Suppl. 14):1996;15-17.
58. Sillem M., Parviz M., Woitge H.W.et al. Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin. Exp. Clin. Endocrinol. Diabet. 107:1999;379-385.
59. Caird L.E., West C.P., Lumsden M.A.et al. Medroxyprogesterone acetate with Zoladex for long-term treatment of fibroids: effects on bone density and patient acceptability. Hum. Reprod. 12:1997;436-440.
60. Prior J.C., Vigna Y.M., Wark J.D.et al. Premenopausal ovariectomy-related bone loss: a randomized, double-blind, 1-year trial of conjugated estrogen or medroxyprogesterone acetate. J. Bone Miner. Res. 12:1997;1851-1863.
61. Surrey E.S. Add-back therapy: extending safety and efficacy of GnRH analogues in the gynecologic patient. Gynecol. Obstet. Invest. 45(Suppl. 1):1998;31-35.
62. Dawood M.Y., Obasiolu C.W., Ramos J.et al. Clinical, endocrine, and metabolic effects of two doses of gestrinone in treatment of pelvic endometriosis. Am. J. Obstet. Gynecol. 176:1997;387-394.
63. Katsuki Y., Takano Y., Futamura Y.et al. Effects of dienogest, a synthetic steroid, on experimental endometriosis in rats. Eur. J. Endocrinol. 138:1998;216-226.
64. De Souza M.J., Miller B.E., Sequenzia L.C.et al. Bone health is not affected by luteal phase abnormalities and decreased ovarian progesterone production in female runners. J. Clin. Endocr. Metab. 82:1997;2867-2876.
65. Hergenroeder A.C., Smith E.O., Shypailo R.et al. Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone acetate or placebo over 12 months. Am. J. Obstet. Gynecol. 176:1997;1017-1025.
66. Gregoriou O., Kouskouni E., Bakas P.et al. Bone mineral density in women with idiopathic hirsutism. Gynecol. Endocrinol. 14:2000;364-368.
67. Udoff L., Langenberg P., Adashi E.Y. Combined continuous hormone replacement therapy: a critical review. Obstet. Gynecol. 86:1996;306-316.
68. Mattson J.S., Cerutis D.R., Parrish L.C. Osteoporosis: a review and its dental implications. Compend. Contin. Educ. Dent. 23:2002;1001-1004.
69. Civitelli R., Pilgram T.K., Dotson M.et al. Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy: a randomized, double-blind, placebo-controlled trial. Arch. Intern. Med. 162:2002;1409-1415.
70. Komulainen M., Kroger H., Tuppurainen M.T.et al. Identification of early postmenopausal women with no bone response to HRT: results of a 5-year clinical trial. Osteoporos. Int. 11:2000;211-218.
71. Salmen T., Heikkinen A.M., Mahonen A.et al. The protective effect of hormone replacement therapy on fracture risk is modulated by estrogen receptor alpha genotype in early postmenopausal women. J. Bone Miner. Res. 15:2000;2479-2486.
72. Mauras N., Vieira N.E., Yergey A.L. Estrogen therapy enhances calcium absorption and retention and diminishes bone turnover in young girls with Turner's syndrome: a calcium kinetic study. Metabolism. 46:1997;908-913.
73. McKane W.R., Khosla S., Burritt M.F.et al. Mechanism of renal calcium conservation with estrogen replacement therapy in women in early menopause: a clinical research center study. J. Clin. Endocr. Metab. 80:1995;3458-3464.
74. Heikkinen A.M., Parviainen M.T., Tuppurainen M.T.et al. Effects of postmenopausal hormone replacement therapy with and without vitamin D3 on circulating levels of 25-hydroxyvitamin D and 1,25-dihydroxy Vitamin D. Calcif. Tissue Int. 62:1998;26-30.
75. Gallagher J.C., Kable W.T., Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am. J. Med. 90:1991;171-178.
76. El-Hajj Fuleihan G., Brown E.M., Curtis K.et al. Effects of sequential and daily continuous hormone replacement therapy on indexes of mineral metabolism. Arch. Intern. Med. 152:1992;1904-1909.
77. Grey A.B., Cundy T.F., Reid I.R. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis. Clin. Endocrinol. 40:1994;671-677.
78. Grey A., Cundy T., Evans M.et al. Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogens in late postmenopausal women. Clin. Endocrinol. 44:1996;293-296.
79. Writing group for the PEPI Trial. Effects of hormone therapy on bone mineral density. JAMA 1996;276:1389-96.
80. Adachi J.D., Sargeant E.J., Sagle M.A. A double-blind randomized controlled trial of the effects of medroxyprogesterone acetate on bone density of women taking estrogen replacement therapy. Br. J. Obstet. Gynecol. 104:1997;64-70.
81. Mizunuma H., Okano H., Soda M.et al. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study. Maturitas. 27:1997;69-76.
82. Felson D.T., Zhang Y., Hannan M.T.et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N. Engl. J. Med. 329:1993;1141-1146.
83. Wimalawansa S.J. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am. J. Med. 104:1998;219-226.
84. Chesnut C.H. 3rd, Bell N.H., Clark G.S.et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am. J. Med. 102:1997;29-37.
85. Williams S.R., Frenchek B., Speroff T.et al. A study of combined continuous ethynylestradiol and norethindrone acetate for postmenopausal hormone replacement. Am. J. Obstet. Gynecol. 162:1990;438-446.
86. Morabito N., Crisafulli A., Vergara C.et al. Effects of genistein and hormone replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J. Bone Miner. Res. 17:2002;1904-1912.
87. Nordin B.E.C., Burnet R.B., Fitzgerald S.et al. Bone densitometry in clinical practice: longitudinal measurements at three sites in postmenopausal women on five treatments. Climacteric. 4:2001;235-242.
88. Mosekilde L., Beck-Nielsen H., Sorensen O.H.et al. Hormone replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study. Maturitas. 31:2000;181-193.
89. Genant H.K., Lucas J., Weiss S. Low-dose esterified estrogens therapy: effects on bone, plasma estradiol concentrations, endometrium and lipid levels. Arch. Intern. Med. 157:1997;2609-2615.
90. Lindsay R., Gallagher J.C., Kleerekoper M.et al. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 287:2002;2668-2676.
91. Ettinger B., Genant H.K., Steiger P.et al. Low-dosage micronized 17-beta-estradiol prevents bone loss in postmenopausal women. J. Obstet. Gynecol. 166:1992;479-488.
92. Castelo-Branco C., Pons F., Gonzalez-Merlo J. Bone mineral density in surgically postmenopausal women receiving hormonal replacement therapy as assessed by dual photon absorptiometry. Maturitas. 16:1993;133-137.
93. Evans S.F., Davie M.W. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages. Clin. Endocrinol. 44:1996;79-84.
94. Studd J.W., MacCarthy K., Zamblera D.et al. Efficacy and safety of Menorest (50. μg/day) compared to Premarin 0.625 mg in the treatment of menopausal symptoms and the prevention of bone loss, in menopausal women. A single-center, comparative, randomized, double-blind, double-dummy study Scand. J. Rheumatol. Suppl. 103:1996;89-90.
95. De Aloysio D., Rovat L.C., Cadossi R.et al. Bone effects of transdermal hormone replacement therapy in postmenopausal women as evaluated by means of ultrasound: an open 1-year prospective study. Maturitas. 27:1997;61-68.
96. Jewelewicz R. New developments in topical estrogen therapy. Fertil. Steril. 67:1996;1-12.
97. O'Sullivan A.J., Crampton L.J., Freund J.et al. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J. Clin. Invest. 102:1998;1035-1040.
98. Hirvonen E., Cacciatore B., Wahlstrom T.et al. Effects of transdermal oestrogen therapy in postmenopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch. Brit. J. Obstet. Gynaecol. 104(Suppl. 16):1997;26-31.
99. Heikkinen J., Vaheri R., Kainulainen P.et al. Long-term continuous combined replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen progeston regimens. Osteoporos. Int. 11:2000;929-937.
100. Hirvonen E., Lamberg Allardt C., Lankinen K.S.et al. Transdermal oestradiol gel in the treatment of the climacterium: a comparison with oral therapy. Br. J. Obstet. Gynaecol. 104(Suppl. 16):1997;19-25.
101. Naessen T., Berglund L., Ulmsten U. Bone loss in elderly women prevented by ultralow doses of parenteral 17 beta-estradiol. Am. J. Obstet. Gynecol. 177:1997;115-119.
102. Nigel Holland E.F., Leather A.T., Studd J.W.W. Increase in bone mass of older postmenopausal women with low mineral bone density after one year of percutaneous oestradiol implants. Br. J. Obstet. Gynecol. 102:1995;238-242.
103. Ryde S.J.S., Bowen-Simpkins K., Bowen-Simkins P.et al. The effect of oestradiol implants on regional and total bone mass: a three-year longitudinal study. Clin. Endocrinol. 40:1994;33-38.
104. Itoi H., Minakami H., Sato I. Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen, 1-alpha-hydroxyvitamin D3 and calcium lactate on vertebral bone loss in early menopausal women. Maturitas. 28:1997;11-17.
105. Studd J., Pornel B., Marton I.et al. Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomized dose-response study. Lancet. 353:1999;1574-1578.
106. De Valk-de Roo G.W., Netelenbos J.C., Peters-Muller I.R.et al. Continuously combined hormone replacement therapy and bone turnover: the influence of dydrogesterone dose, smoking and initial degree of bone turnover. Maturitas. 28:1997;153-162.
107. Foster R.H., Balfour J.A. Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women. Drugs Aging. 11:1997;309-332.
108. Cooper C., Stakkestad J.A., Radowicki S.et al. Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. Osteoporos. Int. 9:1999;358-366.
109. Stevenson J.C., Teter P., Lees B. 17beta-estradiol (1. mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women Maturitas. 38:2001;197-203.
110. Lees B., Stevenson J.C. The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17beta and dydrogesterone. Osteoporos Int. 12:2001;251-258.
111. Bjarnason N.H., Alexandersen P., Christiansen C. Number of years since menopause: spontaneous bone loss is dependent but response to hormone replacement therapy is independent. Bone. 30:2002;637-642.
112. Belaïsch J., Delchambre J. Progestatifs et os. Contracept Fertil. Sex. 21:1993;853-860.
113. Komulainen M, Kroger H, Tuppurainen, et al. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial. J Clin Endocrin Metab 1999;84:546-52.
114. Tinelli F.G., Tinelli A., Sena T. Clinical effects of hormone replacement therapy with estradiol valerate and cyproterone acetate in perimenopausal women. Minerva Ginecol. 54:2002;67-73.
115. Riis B.J., Thomsen K., Strom V.et al. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am. J. Obstet. Gynecol. 156:1987;61-65.
116. Christiansen C., Riis B.J. Five years with continuous combined oestrogen/progestogen therapy: Effects on calcium metabolism, lipoproteins, and bleeding pattern. Br. J. Obstet. Gynecol. 97:1990;1087-1092.
117. Christiansen C., Riis B.J. 17beta-Estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J. Clin. Endocr. Metab. 71:1990;836-841.
118. Klehr-Bahrmann I., Kuhl H. Formation of ethinylestradiol in postmenopausal women during continuous treatment with a combination of estradiol, estriol and norethisterone acetate. Maturitas. 21:1995;245-250.
119. Riis B.J., Johansen J., Christiansen C. Continuous oestrogen-progestogen treatment and bone metabolism in postmenopausal women. Maturitas. 10:1988;51-58.
120. Eiken P., Pors Nielsen S., Kolthoff N. Effects on bone mass after eight years of hormonal replacement therapy. Br. J. Obstet. Gynecol. 104:1997;702-707.
121. Riis B.J., Lehrmann H.-J., Christiansesn C. Norethisterone acetate in combination with estrogen: effects on the skeleton and other organs. Am. J. Obstet. Gynecol. 187:2002;1101-1116.
122. Bunyavejchevin S., Limpaphayom K.K. The metabolic and bone density effects of continuous combined 17-beta estradiol and norethisterone acetate treatment in Thai postmenopausal women: a double-blind placebo-controlled trial. J. Med. Assoc. Thai. 84:2001;45-53.
123. Saure A., Hirvonen E., Tikkanen M.J.et al. A novel oestradiol- desogestrel preparation for hormone replacement therapy: effects on hormones, lipids, bone, climacteric symptoms and endometrium. Maturitas. 16:1993;1-12.
124. Paoletti A.M., Pilloni M., Orru M.et al. Efficacy and safety of oral and transdermal hormonal replacement treatment containing levonorgestrel. Maturitas. 42:2002;137-147.
125. Zartarian M., Micheletti M.C., Gauthier A.et al. Effects on the quality of menstrual cycles and hot flushes of nomegestrol acetate used alone or associated with cutaneous 17 beta estradiol in inversed sequence in perimenopausal women. Contracept. Fertil. Sex. 26:1998;69-76.
126. Curran M.P., Wagstaff A.J. Estradiol and norgestimate: a review of their combined use as hormone replacement therapy in postmenopausal women. Drugs Aging. 18:2001;863-865.
127. Tobias J.H., Clarke S., Mitchell K.et al. Analysis of the contribution of dydrogesterone to bone turnover changes in postmenopausal women commencing hormone replacement therapy. J. Clin. Endocrnol. Metab. 86:2001;1194-1198.
128. Trémollieres F., Pouilles J.M., Ribot C. Effect of long term administration of progestogen on postmenopausal bone loss: result of a two-year controlled study. Clin. Endocrinol. 38:1993;627-631.
129. Bouali Y., Gaillard-Kelly M., Marie P.J. Effect of trimegestone alone or in combination with estradiol on boner mass and bone turnover in an adult rat model of osteopenia. Gynecol. Endocrinol. 15:2001;48-55.
130. Lepescheux L., Secchi J., Gaillard-Kelly M.et al. Effects of 17-beta-estradiol and trimegestone alone, and in combination, on the bone and uterus of ovariectomized rats. Gynecol. Endocrinol. 15:2001;312-320.
131. Farish E., Barnes J.F., O'Donoghue E.et al. The role of megestrol acetate as an alternative to conventional hormone replacement therapy. Climacteric. 3:2000;125-134.
132. Onobrakpeya O.A., Fall P.M., Willard A.et al. Effect of norethindrone acetate on hormone levels and markers of bone turnover in estrogen-treated postmenopausal women. Endocr. Res. 27:2001;473-480.
133. Banks E., Berrington A., Casabonne D. Overview of the relationship between use of progestogen-only contraceptives and bone mineral density. Br. J. Obstet. Gynecol. 108:2001;1214-1221.
134. Dören M., Samsioe G. Prevention of postmenopausal osteoporosis with estrogen replacement therapy and associated compounds: update on trials since 1995. Hum. Reprod. Update. 6:2000;419-426.